Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CVRX Stock Forecast 2026-2027
$7.53
Current Price
$198.13M
Market Cap
Buy 6
Hold 0
Sell 1
Wall St Analyst Ratings
Distance to CVRX Price Targets
+85.9%
To High Target of $14.00
+59.4%
To Median Target of $12.00
-20.3%
To Low Target of $6.00
CVRX Price Momentum
-8.7%
1 Week Change
+52.1%
1 Month Change
-34.2%
1 Year Change
+6.1%
Year-to-Date Change
-43.6%
From 52W High of $13.34
+75.2%
From 52W Low of $4.30
📊 TOP ANALYST CALLS
Did CVRX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if CVRx is one of their latest high-conviction picks.
Latest CVRX Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, CVRX has a bullish consensus with a median price target of $12.00 (ranging from $6.00 to $14.00). The overall analyst rating is N/A (N/A/10). Currently trading at $7.53, the median forecast implies a 59.4% upside. This outlook is supported by 6 Buy, 0 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Frank Takkinen at Lake Street, projecting a 85.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CVRX Analyst Ratings
6
Buy
0
Hold
1
Sell
CVRX Price Target Range
Low
$6.00
Average
$12.00
High
$14.00
Current: $7.53
Latest CVRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CVRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 13, 2026 | Canaccord Genuity | William Plovanic | Buy | Maintains | $10.00 |
| Nov 6, 2025 | Canaccord Genuity | William Plovanic | Buy | Maintains | $11.00 |
| Nov 6, 2025 | Cantor Fitzgerald | Ross Osborn | Overweight | Maintains | $13.00 |
| Aug 5, 2025 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $11.00 |
| May 9, 2025 | JP Morgan | Robbie Marcus | Underweight | Downgrade | $7.00 |
| May 9, 2025 | Piper Sandler | Matt O'Brien | Overweight | Maintains | $12.00 |
| Apr 8, 2025 | Canaccord Genuity | William Plovanic | Buy | Maintains | $18.00 |
| Apr 8, 2025 | Lake Street | Frank Takkinen | Buy | Maintains | $14.00 |
| Feb 5, 2025 | Canaccord Genuity | William Plovanic | Buy | Maintains | $23.00 |
| Feb 5, 2025 | Piper Sandler | Matt O'Brien | Overweight | Maintains | $20.00 |
| Jan 17, 2025 | Craig-Hallum | Alexander Nowak | Buy | Maintains | $22.00 |
| Jan 14, 2025 | William Blair | Margaret Kaczor | Outperform | Upgrade | $N/A |
| Dec 9, 2024 | Canaccord Genuity | William Plovanic | Buy | Maintains | $22.00 |
| Nov 4, 2024 | Craig-Hallum | Alexander Nowak | Buy | Maintains | $20.00 |
| Oct 30, 2024 | Piper Sandler | Matt O'Brien | Overweight | Reiterates | $16.00 |
| Oct 30, 2024 | Canaccord Genuity | William Plovanic | Buy | Maintains | $17.00 |
| Oct 30, 2024 | Lake Street | Frank Takkinen | Buy | Maintains | $15.00 |
| Oct 23, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $14.00 |
| Sep 10, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Initiates | $14.00 |
| Aug 26, 2024 | Lake Street | Frank Takkinen | Buy | Reiterates | $12.00 |
CVRx, Inc. (CVRX) Competitors
The following stocks are similar to CVRx based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CVRx, Inc. (CVRX) Financial Data
CVRx, Inc. has a market capitalization of $198.13M with a P/E ratio of -3.7x. The company generates $56.65M in trailing twelve-month revenue with a -94.1% profit margin.
Revenue growth is +4.4% quarter-over-quarter, while maintaining an operating margin of -69.8% and return on equity of -96.6%.
Valuation Metrics
Market Cap
$198.13M
Enterprise Value
$170.55M
P/E Ratio
-3.7x
PEG Ratio
-0.5x
Price/Sales
3.5x
Growth & Margins
Revenue Growth (YoY)
+4.4%
Gross Margin
+86.3%
Operating Margin
-69.8%
Net Margin
-94.1%
EPS Growth
+4.4%
Financial Health
Cash/Price Ratio
+38.2%
Current Ratio
7.6x
Debt/Equity
128.4x
ROE
-96.6%
ROA
-26.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
CVRx, Inc. (CVRX) Business Model
About CVRx, Inc.
What They Do
Develops therapies for cardiovascular conditions.
Business Model
CVRx, Inc. generates revenue primarily through the sale of its medical device, the Barostim Neo, which is aimed at improving heart function for patients with chronic heart failure. The company collaborates with healthcare providers and institutions to promote its innovative neuromodulation therapies as alternatives to traditional drug treatments.
Additional Information
Headquartered in Minneapolis, Minnesota, CVRx is committed to advancing patient care and focuses on ongoing research and development to enhance its technology and expand its applications in heart health management. The company is positioned within the growing medical technology industry, contributing to the evolution of non-invasive treatment options for cardiovascular diseases.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
223
CEO
Mr. Kevin Hykes
Country
United States
IPO Year
2021
Website
www.cvrx.comCVRx, Inc. (CVRX) Latest News & Analysis
Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX
10 days ago
Quick Summary
Pomerantz LLP is investigating claims for CVRx, Inc. (NASDAQ: CVRX) investors. Interested parties should contact Danielle Peyton at the provided email or phone number.
Why It Matters
CVRx is under investigation, which could indicate potential legal troubles or financial instability, impacting its stock value and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
CVRx, Inc. will present scientific findings on Barostim therapy at the THT meeting in Boston from March 2-4, 2026, focusing on its neuromodulation solutions for cardiovascular diseases.
Why It Matters
CVRx's presentation at a key cardiovascular conference highlights its innovative Barostim therapy, potentially boosting investor confidence in its growth and market position.
Source: GlobeNewsWire
Market Sentiment:
Neutral
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX
17 days ago
Quick Summary
Pomerantz LLP is investigating claims for CVRx, Inc. (NASDAQ: CVRX) investors. Interested parties should contact Danielle Peyton at the provided email or phone number.
Why It Matters
The investigation into CVRx may signal potential legal or financial troubles, prompting investors to reassess their positions and risk exposure in the company.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Glancy Prongay Wolke & Rotter LLP is investigating CVRx, Inc. (NASDAQ: CVRX) for potential violations of federal securities laws, urging affected investors to inquire about recovery options.
Why It Matters
The investigation into CVRx for potential securities law violations could signal financial instability, affecting stock prices and investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
The Law Offices of Frank R. Cruz are investigating CVRx, Inc. (NASDAQ: CVRX) for potential federal securities law violations following disappointing Q1 2025 revenue results.
Why It Matters
CVRx faces a securities investigation, signaling potential legal and financial issues that could affect stock performance and investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
The Law Offices of Howard G. Smith are investigating CVRx, Inc. (NASDAQ: CVRX) for potential violations of federal securities laws. Investors who incurred losses are encouraged to contact the firm.
Why It Matters
Legal investigations can signal potential financial instability or regulatory issues for CVRx, which may lead to stock price volatility and affect investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About CVRX Stock
What is CVRx, Inc.'s (CVRX) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, CVRx, Inc. (CVRX) has a median price target of $12.00. The highest price target is $14.00 and the lowest is $6.00.
Is CVRX stock a good investment in 2026?
According to current analyst ratings, CVRX has 6 Buy ratings, 0 Hold ratings, and 1 Sell ratings. The stock is currently trading at $7.53. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CVRX stock?
Wall Street analysts predict CVRX stock could reach $12.00 in the next 12 months. This represents a 59.4% increase from the current price of $7.53. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is CVRx, Inc.'s business model?
CVRx, Inc. generates revenue primarily through the sale of its medical device, the Barostim Neo, which is aimed at improving heart function for patients with chronic heart failure. The company collaborates with healthcare providers and institutions to promote its innovative neuromodulation therapies as alternatives to traditional drug treatments.
What is the highest forecasted price for CVRX CVRx, Inc.?
The highest price target for CVRX is $14.00 from Frank Takkinen at Lake Street, which represents a 85.9% increase from the current price of $7.53.
What is the lowest forecasted price for CVRX CVRx, Inc.?
The lowest price target for CVRX is $6.00 from at , which represents a -20.3% decrease from the current price of $7.53.
What is the overall CVRX consensus from analysts for CVRx, Inc.?
The overall analyst consensus for CVRX is bullish. Out of 8 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 1 as Sell, with a median price target of $12.00.
How accurate are CVRX stock price projections?
Stock price projections, including those for CVRx, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 14, 2026 2:34 AM UTC